CY1111702T1 - Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1 - Google Patents

Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1

Info

Publication number
CY1111702T1
CY1111702T1 CY20111100700T CY111100700T CY1111702T1 CY 1111702 T1 CY1111702 T1 CY 1111702T1 CY 20111100700 T CY20111100700 T CY 20111100700T CY 111100700 T CY111100700 T CY 111100700T CY 1111702 T1 CY1111702 T1 CY 1111702T1
Authority
CY
Cyprus
Prior art keywords
indolo
producers
receptor
race
receptor race
Prior art date
Application number
CY20111100700T
Other languages
Greek (el)
English (en)
Inventor
Mahmood Ahmed
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111702(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1111702T1 publication Critical patent/CY1111702T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
CY20111100700T 2006-12-21 2011-07-19 Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1 CY1111702T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds
EP07857808A EP2091949B1 (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
CY1111702T1 true CY1111702T1 (el) 2015-10-07

Family

ID=39283563

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100700T CY1111702T1 (el) 2006-12-21 2011-07-19 Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY20121100862T CY1113131T1 (el) 2006-12-21 2012-09-20 Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100862T CY1113131T1 (el) 2006-12-21 2012-09-20 Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1

Country Status (32)

Country Link
US (1) US8101775B2 (cg-RX-API-DMAC7.html)
EP (2) EP2091949B1 (cg-RX-API-DMAC7.html)
JP (1) JP5309034B2 (cg-RX-API-DMAC7.html)
KR (1) KR101495927B1 (cg-RX-API-DMAC7.html)
CN (1) CN103012390B (cg-RX-API-DMAC7.html)
AR (1) AR064452A1 (cg-RX-API-DMAC7.html)
AT (1) ATE509927T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007336224B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0721127A2 (cg-RX-API-DMAC7.html)
CA (1) CA2673468C (cg-RX-API-DMAC7.html)
CL (1) CL2007003755A1 (cg-RX-API-DMAC7.html)
CR (2) CR10922A (cg-RX-API-DMAC7.html)
CY (2) CY1111702T1 (cg-RX-API-DMAC7.html)
DK (2) DK2091949T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2009000133A (cg-RX-API-DMAC7.html)
EA (1) EA017406B1 (cg-RX-API-DMAC7.html)
ES (1) ES2389879T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20110456T1 (cg-RX-API-DMAC7.html)
IL (1) IL199187A (cg-RX-API-DMAC7.html)
JO (1) JO2701B1 (cg-RX-API-DMAC7.html)
MA (1) MA30999B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009006882A (cg-RX-API-DMAC7.html)
MY (2) MY148470A (cg-RX-API-DMAC7.html)
NO (1) NO20092385L (cg-RX-API-DMAC7.html)
NZ (1) NZ577387A (cg-RX-API-DMAC7.html)
PE (2) PE20081398A1 (cg-RX-API-DMAC7.html)
PL (2) PL2206710T3 (cg-RX-API-DMAC7.html)
PT (2) PT2091949E (cg-RX-API-DMAC7.html)
SG (1) SG177914A1 (cg-RX-API-DMAC7.html)
SI (2) SI2091949T1 (cg-RX-API-DMAC7.html)
TW (1) TWI393564B (cg-RX-API-DMAC7.html)
WO (1) WO2008074821A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2003132E (pt) 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
DE602008005285D1 (de) * 2007-04-19 2011-04-14 Glaxo Group Ltd Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) -agonisten
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
MY156381A (en) 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
UY31922A (es) * 2008-06-20 2010-01-05 Glaxo Group Ltd Compuestos
EP2695615A3 (en) * 2008-07-23 2014-04-30 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010011316A1 (en) 2008-07-23 2010-01-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
KR101800595B1 (ko) * 2008-08-27 2017-11-22 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한, ｓ1ｐ1 수용체 효능제로서의 치환된 트리시클릭 산 유도체
WO2010069949A1 (en) * 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
MY161854A (en) 2009-11-13 2017-05-15 Receptos Inc Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2513095A4 (en) * 2009-12-18 2013-05-15 Glaxo Group Ltd OXADIAZOLSUBSTITUTED INDAZONE DERIVATIVES FOR USE AS SPHINGOSIN-1-PHOSPHATE-1 (S1P1) RECEPTOR AGONISTS
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CA2789480A1 (en) * 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
EP2672823B1 (en) 2011-02-07 2016-08-24 Biogen MA Inc. S1p modulating agents
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP3242666B9 (en) 2015-01-06 2024-12-25 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
BR112019001153A2 (pt) * 2016-07-22 2019-04-30 Shijiazhuang Sagacity New Drug Development Co., Ltd. agonista s1p1 e aplicação do mesmo
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
NZ789014A (en) 2019-12-03 2025-07-25 Lg Chemical Ltd Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient
BR112022015723A2 (pt) * 2020-02-11 2023-02-14 Syngenta Crop Protection Ag Compostos de amina cíclica pesticidamente ativos
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US7199142B2 (en) 2002-06-17 2007-04-03 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
WO2004103279A2 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
JP2007528872A (ja) 2003-10-01 2007-10-18 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物
CA2547198A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
MX2007010112A (es) 2005-02-25 2007-10-12 Ono Pharmaceutical Co Compuesto indol y uso del mismo.
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
AU2006240789B2 (en) 2005-04-22 2010-03-04 Daiichi Sankyo Company, Limited Heterocyclic compound
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
JP2009506046A (ja) 2005-08-23 2009-02-12 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制剤化合物および組成物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
PT2003132E (pt) * 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
SI2069336T1 (sl) 2006-09-07 2013-03-29 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot imunomodulirna sredstva
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
DE602008005285D1 (de) 2007-04-19 2011-04-14 Glaxo Group Ltd Oxadiazolsubstituierte indazolderivate zur verwendung als sphingosin-1-phosphat (s1p) -agonisten

Also Published As

Publication number Publication date
EP2091949B1 (en) 2011-05-18
ES2389879T3 (es) 2012-11-02
EP2206710A1 (en) 2010-07-14
HK1130255A1 (en) 2009-12-24
DK2091949T3 (da) 2011-07-18
CA2673468A1 (en) 2008-06-26
JP5309034B2 (ja) 2013-10-09
PE20121076A1 (es) 2012-09-05
PL2206710T3 (pl) 2012-11-30
AR064452A1 (es) 2009-04-01
BRPI0721127A2 (pt) 2014-03-11
CN103012390B (zh) 2015-08-26
CL2007003755A1 (es) 2008-08-22
SI2091949T1 (sl) 2011-08-31
CR10922A (es) 2009-08-12
CY1113131T1 (el) 2016-04-13
PE20081398A1 (es) 2008-11-19
SI2206710T1 (sl) 2012-10-30
MY148470A (en) 2013-04-30
NO20092385L (no) 2009-08-24
JP2010513397A (ja) 2010-04-30
DOP2009000133A (es) 2009-08-15
HRP20120685T1 (hr) 2012-09-30
DK2206710T3 (da) 2012-08-27
CN103012390A (zh) 2013-04-03
PL2091949T3 (pl) 2011-10-31
US8101775B2 (en) 2012-01-24
PT2206710E (pt) 2012-09-10
EP2206710B1 (en) 2012-07-04
MX2009006882A (es) 2009-07-03
IL199187A0 (en) 2010-03-28
TW200843736A (en) 2008-11-16
SG177914A1 (en) 2012-02-28
HRP20110456T1 (hr) 2011-07-31
EA017406B1 (ru) 2012-12-28
CR20140316A (es) 2014-08-20
HK1140761A1 (en) 2010-10-22
ATE509927T1 (de) 2011-06-15
EA200970612A1 (ru) 2009-10-30
NZ577387A (en) 2012-01-12
MA30999B1 (fr) 2009-12-01
KR101495927B1 (ko) 2015-02-25
EP2091949A1 (en) 2009-08-26
WO2008074821A1 (en) 2008-06-26
PT2091949E (pt) 2011-07-13
JO2701B1 (en) 2013-03-03
AU2007336224B2 (en) 2013-01-10
IL199187A (en) 2015-04-30
AU2007336224A1 (en) 2008-06-26
US20100113796A1 (en) 2010-05-06
CA2673468C (en) 2015-06-02
KR20090092290A (ko) 2009-08-31
MY156822A (en) 2016-03-31
TWI393564B (zh) 2013-04-21

Similar Documents

Publication Publication Date Title
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
CY1110115T1 (el) Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες
CY1118061T1 (el) Δικυκλικα παραγωγα heterocyclyl σαν καταστολεις κινασης (kinase) fgfr για θεραπευτικη χρηση
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1115836T1 (el) Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
CY1112724T1 (el) Παραγωγα ανθρακικης κουινουκλιδινης και ιατρικη συνθεση αυτων
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CY1113573T1 (el) Selurampanel
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
SE0401762D0 (sv) Novel compounds
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
CY1114400T1 (el) Θεραπευτικες εφαρμογες των παραγωγων κιναζολινεδιονης